Mona Salem Samra

Mona Salem Samra

Auto-generated profile, based on publicly available information

Mona Salem Samra

Staffordshire children's hospital, University hospitals of north midlands, Staffordshire, United Kingdom

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
MSMona Salem Samra
Mona Salem Samra
DLDae Hyun Lim
Dae Hyun Lim
MHMan Yong Han
Man Yong Han
HJHye Mi Jee
Hye Mi Jee
YKYoon Keun Kim
Yoon Keun Kim
JKJeong Hee Kim
Jeong Hee Kim
Samra MS, et al. Allergy Asthma Immunol Res. 2021 Jan;13(1):56-74. https://doi.org/10.4168/aair.2021.13.1.56

9 November 2018 in International Archives of Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
MSMona Samra
Mona Samra
SNSoo Kyung Nam
Soo Kyung Nam
DLDae Hyun Lim
Dae Hyun Lim
DKDong Hyun Kim
Dong Hyun Kim
Jinho YangJinho Yang
Jinho Yang
JKJeong Hee Kim
Jeong Hee Kim
Background: Microbiota and human allergic airway diseases have been proven to be interrelated. Bacteria-derived extracellular vesicle (EV)s are known to play important roles in interbacterial and human-bacteria communications, but their relationship with allergies has not been examined yet. Urine EVs were investigated to determine whether they could be used as biomarkers for monitoring allergic airway diseases in children. Methods: Subjects were 4 groups of chronic rhinitis (CR), allergic rhinitis (AR), atopic asthma (AS) and healthy controls. Single voided urine samples were collected. Urine EVs were isolated and their DNA was extracted for 16S-rDNA pyrosequencing. Results: A total of 118 children participated in this study; 27, 39, 19, and 33 were in the CR, AR, AS, and control group, respectively. The AR had a significantly high Chao-1 index than that of controls. Principal component analysis revealed dysbiosis in the CR, AR, and AS compared to the controls. One phylum and 19 families and genera were significantly enriched or depleted in the disease groups compared to the controls; the Actinobacteria phylum and the Sphingomonadaceae family were more abundant in the AS and CR, the Comamonadaceae family, the Propionibacteraceae family, Propionibacterium and Enhydrobacter were more enriched in the CR, and the Methylobacteriaceae family and Methylobacterium were more abundant in each disease group, while the Enterobacteriaceae family was depleted in each disease group. Conclusions: CR, AR, and AS had a distinct composition of urine EVs. Urine EVs could be an indicator for assessing allergic airway diseases in children.

15 February 2024 in Clinical and Experimental Pediatrics
Verified
Journal Article
Open access
PDF file
JKJeong Hee Kim
Jeong Hee Kim
MSMona Salem Samra
Mona Salem Samra
Atopic dermatitis (AD) is a lifelong disease that markedly impairs quality of life. AD is considered a starting point of the “atopic march,” which begins at a young age and may progress to systemic allergic diseases. Moreover, it is strongly associated with comorbid allergic and inflammatory diseases including arthritis and inflammatory bowel disease. Understanding the pathogenesis of AD is essential for the development of targeted therapies. Epidermal barrier dysfunction, immune deviation toward a T helper 2 proinflammatory profile, and microbiome dysbiosis play important roles via complex interactions. The systemic involvement of type 2 inflammation, wheather acute or chronic, and whether extrinsic or intrinsic, is evident in any type of AD. Studies on AD endotypes with unique biological mechanisms have been conducted according to clinical phenotypes, such as race or age, but the endotype for each phenotype, or endophenotype, has not yet been clearly identified. Therefore, AD is still being treated according to severity rather than endotype. Infancy-onset and severe AD are known risk factors leading to atopic march. In addition, up to 40% of adult AD are cases of infancy-onset AD that persist into adulthood, and these are often accompanied by other allergic diseases. Therefore, early intervention strategies to identify high-risk infants and young children, repair an impaired skin barrier, and control systemic inflamation may improve long-term outcomes in AD patients. However, to the best of our knowledge, no study has evaluated the effectiveness of early intervention on atopic march using systemic therapy in high-risk infants. This narrative review addresses the latest knowledge of systemic treatment, including Th2 cytokine receptor antagonists and Janus kinase inhibitors, for children with moderate to severe AD that is refractory to topical treatment.

1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HWHyeonjin Woo
Hyeonjin Woo
MSMona Salem Samra
Mona Salem Samra
DLDae Hyun Lim
Dae Hyun Lim
JKJeong Hee Kim
Jeong Hee Kim
Woo H, et al. J Korean Med Sci. 2021 May;36(19):e130. https://doi.org/10.3346/jkms.2021.36.e130